Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reaction Biology Top-Ranked in Kinase Profiling Survey

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
RBC also ranked highly on technical support and data quality.

Reaction Biology Corporation ("RBC") has announced that it has received the highest number of positive ratings in a recent industry survey.

HTStec, a UK-based technical research firm, surveyed 78 research labs around the globe for its Kinase Profiling Trends 2013 report. The labs included large pharmas, biotechs, university and non-profit labs.

Survey participants were asked to rate the 16 top kinase profiling outsource providers on eight different attributes.

The provider with the highest number of positive ratings was RBC, which came in number one on customer service, turnaround time, and low cost.

RBC also ranked as the most-used provider to the industry, rising from fifth place in the same survey taken in 2010.

“We are very pleased with this validation of our efforts to provide the widest coverage of the kinome, with a gold standard activity assay,” said Dr. Haiching Ma, Chief Science Officer of RBC.

Dr. Ma continued, “Eighty-eight percent of all pharmas in the survey preferred activity-based assays, and RBC’s radiolabeled HotSpot assay now provides high-quality reproducible data on 457 kinases.”

The survey estimated that RBC had the largest share of the $34 million kinase profiling market.

Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services. With more than 450 kinases, RBC’s coverage of the kinome is the broadest in the industry.

Using its proprietary HotSpotSM technology and other innovations, RBC is expanding its already substantial production of epigenetic regulatory enzymes.

RBC has provided its services to over 300 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reaction Biology and Cisbio Sign Distribution Agreement
Agreement will see Cisbio distribute Reaction Biology's epigenetic proteins.
Friday, January 17, 2014
Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!